Protective Effects of Dietary Supplementation with a Combination of Nutrients in a Transgenic Mouse Model of Alzheimer's Disease

Shengyuan Wang, Yu Cui, Chao Wang, Wei Xie, Lan Ma, Jinfeng Zhu, Yan Zhang, Rui Dang, Decai Wang, Yonghui Wu, Qunhong Wu, Shengyuan Wang, Yu Cui, Chao Wang, Wei Xie, Lan Ma, Jinfeng Zhu, Yan Zhang, Rui Dang, Decai Wang, Yonghui Wu, Qunhong Wu

Abstract

Objective: This study investigated the effects of intervention with a combination of nutrients in the amyloid precursor protein-presenilin (APP-PSN) C57BL/6J double transgenic mouse model of Alzheimer's disease (AD).

Methods: A total of 72 2-month-old APP-PSN mice were randomly assigned to three groups. The model group (MG) was fed regular, unsupplemented chow, while the low- and high-dose treatment groups (LG and HG, respectively) were given a combination of nutrients that included phosphatidylserine, blueberry extracts, docosahexaenoic acid, and eicosapentaenoic acid as part of their diet. An additional 24 wild-type littermates that were fed unsupplemented chow served as the negative control group (NG). After 3 and 7 months of treatment, the cognitive performance was assessed with the Morris water maze and the shuttle box escape/avoidance task, and the biochemical parameters and oxidative stress were evaluated in both the blood and brain.

Results: An improvement in antioxidant capacity was observed in the treatment groups relative to the MG at 3 months, while superior behavioral test results were observed in the mice of the HG and NG groups. In the MG, pycnosis was detected in neuronal nuclei, and a loss of neurons was observed in the cerebral cortex and the hippocampus. At 7 months, the β-amyloid1-42 peptide accumulation was significantly elevated in the MG but was markedly lower in the mice fed the nutrient combination. The antioxidant capacity and behavioral test scores were also higher in these mice.

Conclusions: Early intervention with a combination of nutrients should be considered as a strategy for preventing cognitive decline and other symptoms associated with AD.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1. The possible mechanisms of action…
Fig 1. The possible mechanisms of action of compound nutrients.
Ach: acetylcholine; cAMP: Cycilic adenosine monophospate; APP: amyloid precursor protein-presenilin; Aβ: anti-β-amyloid; GSH-PX: glutathione peroxidase; SOD: superoxide dismutase; TChE: total cholinesterase.
Fig 2. The trend of the average…
Fig 2. The trend of the average weights of the four groups.
Fig 3. Trajectories of mice in the…
Fig 3. Trajectories of mice in the Morris water maze tests.
Fig 4. Results from Morris water maze…
Fig 4. Results from Morris water maze tests.
(A) The average incubation period from the first to fifth day for the four groups. After 3 months and 7 months of intervention, the mice in HG and NG spent much less time searching for new (reversal) hidden platform on each reversal training day compared to MG, * P

Fig 5. Immunofluorescence staining with rabbit anti-Aβ1–42…

Fig 5. Immunofluorescence staining with rabbit anti-Aβ1–42 and HE dyeing of the temporal cortex and…

Fig 5. Immunofluorescence staining with rabbit anti-Aβ1–42 and HE dyeing of the temporal cortex and hippocampus of APP/PSN mice.
(1) LG and HG: APP/PSN (Fig 5A) mice with 7 months of intervention; MG: APP/PSN (Fig 5B) mice without intervention and their wild-type littermates (NG). (2) LG and HG: ±, MG: +++, NG:–(Fig 5C and 5D).
Fig 5. Immunofluorescence staining with rabbit anti-Aβ1–42…
Fig 5. Immunofluorescence staining with rabbit anti-Aβ1–42 and HE dyeing of the temporal cortex and hippocampus of APP/PSN mice.
(1) LG and HG: APP/PSN (Fig 5A) mice with 7 months of intervention; MG: APP/PSN (Fig 5B) mice without intervention and their wild-type littermates (NG). (2) LG and HG: ±, MG: +++, NG:–(Fig 5C and 5D).

References

    1. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer’s disease. Alzheimers Dement. 2007; 3: 186–191. 10.1016/j.jalz.2007.04.381
    1. Goedert M, Spillantini M G. A century of Alzheimer's disease. Sci. 2006; 314: 777–781.
    1. McKeith I, Cummings J. Behavioural changes and psychological symptoms in dementia disorders. Lancet Neurol. 2005; 4: 735–742.
    1. Butterfield D A, Swomley A M, Sultana R. Amyloid β-Peptide (1–42)-Induced Oxidative Stress in Alzheimer Disease: Importance in Disease Pathogenesis and Progression. Antioxid Redox Signal. 2013; 19: 823–835. 10.1089/ars.2012.5027
    1. Mastroeni D, Grover A, Delvaux E, Whiteside C, Coleman PD, Rogers J. Epigenetic mechanisms in Alzheimer's disease. Neurobiol Aging. 2011; 32: 1161–1180. 10.1016/j.neurobiolaging.2010.08.017
    1. Pimplikar S W, Nixon R A, Robakis N K, Shen J, Tsai LH. Amyloid-independent mechanisms in Alzheimer's disease pathogenesis. J Neurosci. 2010; 30: 14946–14954. 10.1523/JNEUROSCI.4305-10.2010
    1. Moreira PI, Carvalho C, Zhu X, Smith MA, Perry G. Mitochondrial dysfunction is a trigger of Alzheimer's disease pathophysiology. Biochim Biophys Acta. 2010; 1802: 2–10. 10.1016/j.bbadis.2009.10.006
    1. Bignante E A, Heredia F, Morfini G, Lorenzo A. Amyloid β precursor protein as a molecular target for amyloid β–induced neuronal degeneration in Alzheimer's disease. Neurobiol Aging. 2013; 34: 2525–2537. 10.1016/j.neurobiolaging.2013.04.021
    1. Querfurth HW, LaFerla FM. Alzheimer’s disease. N. Engl. J.Med. 2010, 362, 329–344. 10.1056/NEJMra0909142
    1. Ji HF, Shen L. Berberine: a potential multipotent natural product to combat Alzheimer’s disease. Molecules. 2011; 16: 6732–6740. 10.3390/molecules16086732
    1. Hofrichter J, Krohn M, Schumacher T, Lange C, Feistel B, Walbroel B, et al. Reduced Alzheimer's disease pathology by St. John's Wort treatment is independent of hyperforin and facilitated by ABCC1 and microglia activation in mice. Curr Alzheimer Res. 2013; 10: 1057–1069.
    1. Colantuoni E, Surplus G, Hackman A, Arrighi HM, Brookmeyer R. Web-based application to project the burden of Alzheimer's disease. Alzheimers Dement. 2010; 6: 425–428. 10.1016/j.jalz.2010.01.014
    1. Douaud G, Refsum H, de Jager CA, Jacoby R, Nichols TE, Smith SM, et al. Preventing Alzheimer’s disease-related gray matter atrophy by B-vitamin treatment. Proc Natl Acad Sci U S A. 2013; 110: 9523–9528. 10.1073/pnas.1301816110
    1. Johnson E J. A possible role for lutein and zeaxanthin in cognitive function in the elderly. Am J Clin Nutr. 2012; 96: 1161S–1165S. 10.3945/ajcn.112.034611
    1. Little A, Levy R, Chuaqui-Kidd P, Hand D. A double-blind, placebo controlled trial of high-dose lecithin in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 1985; 48: 736–742.
    1. Hjorth E, Zhu M, Toro VC, Vedin I, Palmblad J, Cederholm T, et al. Omega-3 Fatty Acids Enhance Phagocytosis of Alzheimer's Disease-Related Amyloid-β 42 by Human Microglia and Decrease Inflammatory Markers. J Alzheimers Dis. 2013; 35: 697–713. 10.3233/JAD-130131
    1. Yurko-Mauro K, McCarthy D, Rom D, Nelson EB, Ryan AS, Blackwell A, et al. Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimers Dement. 2010; 6: 456–464. 10.1016/j.jalz.2010.01.013
    1. Scheltens P, Kamphuis PJ Verhey FR, Olde Rikkert MG, Wurtman RJ, Wilkinson D, et al. Efficacy of a medical food in mild Alzheimer’s disease: A randomized, controlled trial. Alzheimers Dement. 2010; 6: 1–10. e1 10.1016/j.jalz.2009.10.003
    1. Kamphuis PJ, Scheltens P. Can nutrients prevent or delay onset of Alzheimer's disease?. J Alzheimers Dis. 2010; 20: 765–775. 10.3233/JAD-2010-091558
    1. Reiserer RS, Harrison FE, Syverud DC, McDonald MP. Impaired spatial learning in the APPSwe+ PSEN1ΔE9 bigenic mouse model of Alzheimer’s disease. Genes Brain Behav. 2007; 6: 54–65.
    1. Nolan JM, Loskutova E, Howard A, Mulcahy R, Moran R, Stack J, et al. The impact of supplemental macular carotenoids in Alzheimer's disease: a randomized clinical trial. J Alzheimers Dis. J Alzheimers Dis. 2015; 44:1157–1169. 10.3233/JAD-142265
    1. Chew EY, Clemons TE, Agrón E, Launer LJ, Grodstein F, Bernstein PS, et al. Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function: The AREDS2 Randomized Clinical Trial. JAMA. 2015; 314: 791–801. 10.1001/jama.2015.9677
    1. Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet. 2004; 13: 159–170.
    1. Reiserer RS, Harrison FE, Syverud DC, McDonald MP. Impaired spatial learning in the APPSwe+ PSEN1DeltaE9 bigenic mouse model of Alzheimer’s disease. Genes Brain Behav. 2007; 6: 54–65.
    1. Subash S, Essa MM, Al-Asmi A, Al-Adawi S, Vaishnav R, Guillemin GJ. Effect of dietary supplementation of dates in Alzheimer's disease APPsw/2576 transgenic mice on oxidative stress and antioxidant status. Nutr Neurosci. 2015; 18: 281–288. 10.1179/1476830514Y.0000000134
    1. Subash S, Essa MM, Braidy N, Awlad-Thani K, Vaishnav R, Al-Adawi S, et al. Guillemin. Diet rich in date palm fruits improves memory, learning and reduces beta amyloid in transgenic mouse model of Alzheimer's disease. J Ayurveda Integr Med. 2015; 6: 111–120. 10.4103/0975-9476.159073
    1. Reeves PG, Nielsen FH, Fahey GC Jr. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr. 1993; 123: 1939–1951.
    1. Garthe A, Kempermann G. An old test for new neurons: refining the Morris water maze to study the functional relevance of adult hippocampal neurogenesis. Front Neurosci. 2013; 7: 63 10.3389/fnins.2013.00063
    1. Dong Z, Bai Y, Wu X, Li H, Gong B, Howland JG, et al. Hippocampal long-term depression mediates spatial reversal learning in the Morris water maze. Neuropharmacology. 2013; 64: 65–73. 10.1016/j.neuropharm.2012.06.027
    1. Banerjee R, Ghosh AK, Ghosh B, Mondal AC, Banerjee R. Effect of chronic inescapable footshock and antidepressant treatment on BDNF/TrkB levels in rat hippocampus. Research and Reviews: A Journal of Neuroscience. 2012; 2: 12–21.
    1. Shi JQ, Shen W, Chen J, Wang BR, Zhong LL, Zhu YW, et al. Anti-TNF-α reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP/PS1 transgenic mouse brains. Brain Res. 2011; 1368: 239–247. 10.1016/j.brainres.2010.10.053
    1. Qiu H, Jin GQ, Jin RF, Zhao WK. Analysis of variance of repeated data measured by water maze with SPSS. Journal of Chinese Integrative Medicine. 2007; 5: 101–105.
    1. Mitew S, Kirkcaldie MT, Dickson TC, Vickers JC. Altered synapses and gliotransmission in Alzheimer's disease and AD model mice. Neurobiol Aging. 2013; 34: 2341–2351. 10.1016/j.neurobiolaging.2013.04.010
    1. Ansari MA, Scheff SW. Oxidative stress in the progression of Alzheimer disease in the frontal cortex. J Neuropathol Exp Neurol. 2010; 69: 155–167. 10.1097/NEN.0b013e3181cb5af4
    1. Reddy VP, Zhu X, Perry G, Smith MA. Oxidative stress in diabetes and Alzheimer's disease. J Alzheimers Dis. 2009; 16: 763–774. 10.3233/JAD-2009-1013
    1. Mangialasche F, Polidori MC, Monastero R, Ercolani S, Camarda C, Cecchetti R, et al. Biomarkers of oxidative and nitrosative damage in Alzheimer's disease and mild cognitive impairment. Ageing Res Rev. 2009; 8: 285–305. 10.1016/j.arr.2009.04.002
    1. Kaladhar D, Anusha N, Rao VV, Surekha C, Meesala S. Regulation of Metabolic Syndromes by means of controlling diseased Ache and Bche with Multitarget Inhibitors through in silico techniques. Journal of Computational Methods in Molecular Design. 2012; 2: 122–129.
    1. Naik RS, Hartmann J, Kiewert C, Duysen EG, Lockridge O, Klein J. Effects of rivastigmine and donepezil on brain acetylcholine levels in acetylcholinesterase-deficient mice. J Pharm Pharm Sci. 2009; 12: 79–85.
    1. Golde TE, Petrucelli L, Lewis J. Targeting Abeta and tau in Alzheimer's disease, an early interim report. Exp Neurol. 2010; 223: 252–266. 10.1016/j.expneurol.2009.07.035
    1. Darreh-Shori T, Soininen H. Effects of cholinesterase inhibitors on the activities and protein levels of cholinesterases in the cerebrospinal fluid of patients with Alzheimer's disease: a review of recent clinical studies. Curr Alzheimer Res. 2010; 7: 67–73.
    1. Hu JJ, Li J, Wei Z, Gu HY, Shao BY, Long DW, et al. The PARF Antagonist AChE Inhibitor PMS777 Attenuates LPS-Induced Acute Neuroinflammation. Neuroscience & Medicine. 2011; 2: 355–362.
    1. Armstrong RA. The pathogenesis of Alzheimer's disease: a reevaluation of the “amyloid cascade hypothesis”. Int J Alzheimers Dis. 2011; 2011:630865 10.4061/2011/630865
    1. Lane RM, Kivipelto M, Greig N H. Acetylcholinesterase and its inhibition in Alzheimer disease. Clinical neuropharmacology. 2004; 27: 141–149.
    1. Munoz-Torrero D. Acetylcholinesterase Inhibitors as Disease-Modifying Therapies for Alzheimers Disease. Current medicinal chemistry. 2008; 15: 2433–2455
    1. Jäger R, Purpura M, Kingsley M. Phospholipids and sports performance. Journal of the International Society of Sports Nutrition. 2007; 4: 5
    1. Parker AG, Gordon J, Thornton A, Byars A, Lubker J, Bartlett M, et al. The effects of IQPLUS Focus on cognitive function, mood and endocrine response before and following acute exercise. J Int Soc Sports Nutr. 2011; 8: 16 10.1186/1550-2783-8-16
    1. Bhalla V, Arora H, Dhir A, Kumar M. A triphenylene based zinc ensemble as an oxidation inhibitor. Chem. Commun. 2012; 48: 4722–4724.
    1. Aliev G, Obrenovich ME, Reddy VP, Shenk JC, Moreira PI, Nunomura A, et al. Antioxidant therapy in Alzheimer’s disease: theory and practice. Mini Rev Med Chem. 2008; 8: 1395–1406.
    1. Tassoni D, Kaur G, Weisinger RS, Sinclair AJ. The role of eicosanoids in the brain. Asia Pacific journal of clinical nutrition. 2008; 17: 220–228.
    1. Clarke R. Lowering blood homocysteine with folic acid-based supplements: meta-analysis of randomised trials. Indian Heart J. 2000; 52: S59–64.

Source: PubMed

3
S'abonner